

INFORMATION STATEMENT

Lund, May 19th, 2009

TFS elects Dr. Wenche Rolfsen as new member of the Board of Directors

TFS Trial Form Support International (TFS) did at the annual general shareholders meeting on April 16th 2009 elect Dr. Wenche Rolfsen, to its Board of Directors.

Dr. Wenche Rolfsen has more than twenty-five years of experience in drug development within the pharmaceutical as well as the CRO industry. She has been actively involved in development and commercialization of pharmaceutical products since 1980. Her experience ranges from development of new drugs to market approval on a global scale. During her 16 years at former Pharmacia & Upjohn, she held a number of senior management position at the Pharmacia cooperation.

During the mid 1990, Dr. Wenche Rolfsen moved from the pharmaceutical industry to join Quintiles, the world's largest CRO. During her 11 years at Quintiles, she held senior executive positions as CEO of the Quintiles Scandinavian offices as well as Vice President Europe for explorative clinical research.

"We are very pleased to welcome Dr. Wenche Rolfsen to our Board of Directors. Her scientific background, academic achievements and extensive clinical development experience combined with exceptional business skills will strengthen TFS ability to improve our customer services and support our current globalization process" said Mr. Daniel Spasic, Chief Executive Officer and Board member at TFS.

Mr. Ulf Rosén, Chairman of the Board adds *"With the addition of Dr. Rolfsen, the Board now represents a broad range of complementary competences and experiences which are important in the vision of making TFS a true global company"*

"I am excited about joining the Board of TFS and I will do everything in my power to support the company in delivering excellence to our customers as well as take active part in the globalization process" said Dr. Wenche Rolfsen, newly elected member of the Board of Directors at TFS.

Dr. Wenche Rolfsen has a broad experience in Board assignments within the life science area as Chairman and member of boards, of which several are listed on NASDAQ OMX Stockholm, Sweden and Oslo börs, Norway. Dr. Wenche Rolfsen currently serves on the Board of Directors of Biovitrum (a Swedish pharmaceutical company), Industrifonden (a foundation that offers venture capital to small- and medium sized companies), Artimplant (a Swedish biomaterials company focusing on orthopedic, odontological and reconstructive surgery), Chairman in Aprea (a Swedish biotechnology



TFS TRIAL FORM SUPPORT INTERNATIONAL

INFORMATION STATEMENT

company with R&D in oncology), Chairman in Denator (a Swedish medical technical company) and Aker Biomarine AS (a Norwegian integrated biotech company).

Dr. Wenche Rolfsen is a pharmacist by training and has a Ph.D from the Pharmaceutical Faculty, Uppsala University, Sweden and has for many years held an adjunct professorship in Pharmacology at the same university.

For further information please contact:

Mr. Daniel Spasic
Chief Executive Officer
TFS Trial Form Support International AB
Telephone: + 46 46 31 32 00

Information about TFS Trial Form Support International (TFS)

TFS Trial Form Support International (TFS), with headquarters in Lund, Sweden, is the largest non-listed European clinical Contract Research Organization (CRO). Clinical services are provided by three business areas; Early Clinical Development, Project Delivery and Contract Placement Solutions, with annual net revenues greater than € 38 million, global operations in 16 countries, and more than 480 employees worldwide. Detailed information on TFS business areas, global locations and recent press releases can be obtained through its website at www.trialformsupport.com



TFS TRIAL FORM SUPPORT INTERNATIONAL